Clinical Trial Update: Second Open Label Extension to Bridging Study CTBM100C2303 [Phase 3]

View source ↗

Summary

Phase 3 open-label extension to a bridging study has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pseudomonas Aeruginosa
• Pulmonary Infections

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Infections, Pseudomonas Aeruginosa | Phase 3 | Status: COMPLETED | Results posted: 2021-06-02